Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03520036 |
Recruitment Status :
Completed
First Posted : May 9, 2018
Results First Posted : January 20, 2023
Last Update Posted : January 20, 2023
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Erythropoietic Protoporphyria (EPP) | Drug: MT-7117 low dose Drug: MT-7117 high dose Drug: Placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 102 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria |
Actual Study Start Date : | July 5, 2018 |
Actual Primary Completion Date : | September 28, 2019 |
Actual Study Completion Date : | September 28, 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: MT-7117 low dose |
Drug: MT-7117 low dose
MT-7117 low dose QD, oral, 16 weeks |
Experimental: MT-7117 high dose |
Drug: MT-7117 high dose
MT-7117 high dose QD, oral, 16 weeks |
Placebo Comparator: Placebo |
Drug: Placebo
Placebo QD, oral, 16 weeks |
- Change From Baseline in Average Daily Time (Minutes) to First Prodromal Symptom Associated With Sunlight Exposure Between Hour Post Sunrise and 1 Hour Pre-Sunset at Week 16. [ Time Frame: Baseline (Week 0) and Week 16 ]Duration in minutes, of sunlight exposure between 1 hour post sunrise and 1 hour pre-sunset. The average Duration in minutes, of sunlight exposure before the first prodromal symptom between 1 hour post sunrise and 1 hour pre-sunset. The average duration means that average of daily durations in 14-day windows before Day 1 (or week 16 Day) applied.
- Change From Baseline in Average Daily Duration (Minutes) of Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-Sunset Without Prodromal Symptoms at Week 16 [ Time Frame: Baseline (Week 0), and Week 16 ]Change from baseline to week 16 in Average Daily Duration (Minutes) of Sunlight Exposure sums any sunlight exposure time excluding any overlapped time with prodromal symptoms, including if the patients go out multiple times on the same day after the prodromal symptom had previously ended.
- Change From Baseline in Average Daily Mean Duration (Minutes) of Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-Sunset Without Prodromal Symptoms at Week 16 [ Time Frame: Baseline (Week 0), and Week 16 ]Change from baseline to week 16 in Average Daily Mean Duration (Minutes) of Sunlight Exposure without prodromal symptoms divided by the number of sunlight exposures periods applicable that day.
- Total Number of Sunlight Exposure Episodes With Prodromal Symptoms During 16-Week Double-Blind Treatment Period [ Time Frame: Week 16 ]
- Change From Baseline in Average Daily Mean Intensity of Prodromal Symptoms During 16-week Double-blind Treatment Period in 11-point Likert Scale [ Time Frame: Baseline (Week 0), and Week 16 ]The Intensity of Prodromal Symptoms is measured by 11-point Likert scale ranges from 0 (no symptom) to 10 (greatest severity of symptom).
- Change From Baseline in Average Daily Duration (Minutes) of Prodromal Symptoms at 16-Week Double-Blind Treatment Period [ Time Frame: Baseline (Week 0), and Week 16 ]
- Change From Baseline in Pigmentation as Measured by Melanin Density for Average of 6 Skin Segments at Week 8 and Week 16. [ Time Frame: Baseline (Week 0), Week 8, and Week 16 ]Pigmentation will be assessed in melanin density which are numeric scores measured by spectrophotometer on 6 skin segments (forehead, left cheek, right inside upper arm, left medial forearm, right-hand side of abdomen, and left-hand side of buttock).
- Percent Change From Baseline in Pigmentation as Measured by Melanin Density for Average of 6 Skin Segments at Week 8 and Week 16. [ Time Frame: Baseline (Week 0), Week 8, and Week 16 ]
- Total Number of Pain Events During 16-Week Double-Blind Treatment Period [ Time Frame: Week 16 ]
- Total Number of Sunlight Exposure Episodes [ Time Frame: Baseline (Week 0) and Week 16 ]
- Change in Pigmentation as Measured by Melanin Density [ Time Frame: Baseline (Week 0) and Week 16 ]
- The Quality of Life as Measured by the Patient Reported Outcomes Measurement Information System (PROMIS) 57 [ Time Frame: Baseline (Week 0) and Week 16 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Additional screening criteria check may apply for qualification.
Inclusion Criteria:
- 1. Subjects provided written informed consent to participate.
- 2. Male and female subjects with a confirmed diagnosis of EPP based on medical history, aged 18 years to 75 years, inclusive, at Screening.
- 3. Subjects are willing and able to travel to the study sites for all scheduled visits.
- 4. In the Investigator's opinion, subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the protocol restrictions and requirements (including travel).
Exclusion Criteria:
- 1. History or presence of photodermatoses other than EPP.
- 2. Subjects who are unwilling or unable to go outside during daylight hours (e.g., between 1 hour post sunrise and 1 hour pre-sunset) during the study.
- 3. Presence of clinically significant hepatobiliary disease based on LFT values at Screening.
- 4. Subjects with AST, ALT, ALP ≥3.0 × upper limit of normal (ULN) or total bilirubin >1.5 × ULN at Screening.
- 5. Subjects with or having a history (in the last 2 years) of excessive alcohol intake in the opinion of the Investigator.
- 6. History or presence of melanoma and/or atypical nevus at Screening.
- 7. History of familial melanoma (defined as having 2 or more first-degree relatives, such as parents, sibling and/or child).
- 8. History or presence of pre-malignant skin lesion squamous cell carcinoma, basal cell carcinoma, or other malignant skin lesions.
- 9. History or presence of psychiatric disease judged to be clinically significant by the Investigator and which may interfere with the study evaluation and/or safety of the subjects.
- 10. Presence of clinically significant acute or chronic renal disease based upon the subject's medical records including hemodialysis; and a serum creatinine level of greater than 1.2 mg/dL or a glomerular filtration rate (GFR) <60 ml/min.
- 11. Presence of any clinically significant disease or laboratory abnormality which, in the opinion of the Investigator, can interfere with the study objectives and/or safety of the subjects.
- 12. Pregnancy or lactation.
- 13. Females of child bearing potential and male subjects with partners of child-bearing potential unwilling to use adequate contraception measures as described in the protocol.
- 14. Treatment with phototherapy within 3 months before Randomization (Visit 2).
- 15. Treatment with afamelanotide within 3 months before Randomization (Visit 2).
- 16. Treatment with cimetidine within 4 weeks before Randomization (Visit 2).
- 17. Treatment with antioxidant agents at doses which, in the opinion of the Investigator, may affect study endpoints (including but not limited to beta-carotene, cysteine, pyridoxine) within 4 weeks before Randomization (Visit 2).
- 18. Chronic treatment with prescription-based analgesic agents including but not limited to opioids and opioid derivatives such as morphine, hydrocodone, oxycodone or their combination with other analgesics or non-steroidal anti-inflammatory drug (NSAID, as Percocet and Vicodin-like prescription drugs) within 4 weeks before Randomization (Visit 2).
- 19. Treatment with any drugs or supplements which, in the opinion of the Investigator, can interfere with the objectives of the study or safety of the subjects.
- 20. Previous exposure to MT 7117.
- 21. Previous treatment with any investigational agent within 12 weeks before Screening OR 5 half-lives of the investigational product (whichever is longer).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03520036
United States, California | |
ACTCA, A Member of the Alliance, Inc. | |
Los Angeles, California, United States, 90036 | |
University of California at San Francisco | |
San Francisco, California, United States, 94143 | |
United States, Florida | |
University of Miami Miller School of Medicine | |
Miami, Florida, United States, 33136 | |
United States, Massachusetts | |
Metro Boston Clinical Partners, LLC | |
Brighton, Massachusetts, United States, 02135 | |
United States, New York | |
Ichan School of Medicine at Mount Sinai | |
New York, New York, United States, 10029 | |
United States, North Carolina | |
Wake Forest Baptist Medical Center | |
Winston-Salem, North Carolina, United States, 27157 | |
United States, Ohio | |
Remington-Davis, Inc | |
Columbus, Ohio, United States, 43215 | |
United States, Texas | |
University of Texas Medical Branch Porphyria Center | |
Galveston, Texas, United States, 77555 | |
United States, Utah | |
University of Utah | |
Salt Lake City, Utah, United States, 84108 |
Study Director: | Head of Clinical Development, | Mitsubishi Tanabe Pharma Development America, Inc. |
Documents provided by Mitsubishi Tanabe Pharma Development America, Inc.:
Responsible Party: | Mitsubishi Tanabe Pharma Development America, Inc. |
ClinicalTrials.gov Identifier: | NCT03520036 |
Other Study ID Numbers: |
MT-7117-A01 |
First Posted: | May 9, 2018 Key Record Dates |
Results First Posted: | January 20, 2023 |
Last Update Posted: | January 20, 2023 |
Last Verified: | December 2022 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Protoporphyria, Erythropoietic Porphyrias, Hepatic Liver Diseases Digestive System Diseases Skin Diseases, Genetic |
Genetic Diseases, Inborn Skin Diseases Porphyrias Metabolic Diseases |